Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA polymerase iota is a specialized, low-fidelity enzyme of the Y family of DNA polymerases, encoded by the POLI gene in humans[5][6]. It is primarily involved in translesion synthesis (TLS), allowing DNA replication to occur across damaged templates—including lesions such as abasic sites and pyrimidine dimers—but it is error-prone and prone to specific misincorporations, especially opposite template thymine[2][3][4][6]. Pol ι also participates to a limited extent in base excision repair (BER) and is implicated in the cellular response to oxidative stress, mediating protection against oxidative DNA damage by interacting with other repair factors like XRCC1[3]. Uniquely, loss or deficiency of DNA polymerase iota causes increased replication rate and checkpoint failure, leading to genomic instability, while overexpression has been observed in various tumor types, suggesting a complex role in cancer biology[1][3].
For conceptual or exploratory inhibitors: Inhibition of translesion DNA synthesis or base excision repair activity, increasing cellular sensitivity to DNA-damaging agents
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase iota (Pol ι (Pol iota)).